Preparation and biodistribution of [131I]linezolid in animal model infection and inflammation

Lambrecht, F. Yurt; Yilmaz, O.; Durkan, K.; Unak, P.; Bayrak, E.
September 2009
Journal of Radioanalytical & Nuclear Chemistry;Sep2009, Vol. 281 Issue 3, p415
Academic Journal
Linezolid is the first of new class of antibiotics, the oxazolidinones, and exhibits activity against many gram-positive organisms, including vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Aim of the study: Linezolid was to label with I-131 and potential of the radiolabeled antibiotic was to investigate in inflamed rats with S. aureus ( S. aureus) and sterile inflamed rats with turpentine oil. Linezolid was labeled with I-131 by iodogen method. Biodistribution of [131I]linezolid was carried out in bacterial inflamed and sterile inflamed rats. Radiolabeling yield of [131I]linezolid was determined as 85 ± 1% at pH 2. After injecting of [131I]linezolid into bacterial inflamed and sterile inflamed rats, radiolabeled linezolid was rapidly removed from the circulation via the kidneys. Binding of [131I]linezolid to bacterial inflamed muscle (T/NT = 77.48 at 30 min) was five times higher than binding to sterile inflamed muscle (T/NT = 14.87 at 30 min) of rats. [131I]linezolid showed good localization in bacterial inflamed tissue. It was demonstrated that [131I]linezolid can be used to detect S. aureus inflammation in rats.


Related Articles

  • In vivo antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic. Li, Guo-Qing; Bai, Xiao-Gang; Li, Cong-Ran; Yang, Xin-Yi; Hu, Xin-Xin; Yuan, Min; Zhang, Wei-Xin; Lou, Ren-Hui; Guo, Hui-Yuan; Jiang, Jian-Dong; You, Xue-Fu // Journal of Antimicrobial Chemotherapy (JAC);Apr2012, Vol. 67 Issue 4, p955 

    Objectives To evaluate the in vivo antibacterial efficacy of chinfloxacin, a novel fluoroquinolone, in murine systemic and local infection models. Methods The efficacy of chinfloxacin in systemic infection was evaluated in a mouse peritonitis model using isolates of methicillin-susceptible...

  • Lactic Acidosis after Treatment with Linezolid. Wiener, M.; Guo, Y.; Patel, G.; Fries, B. C. // Infection;Aug2007, Vol. 35 Issue 4, p278 

    Linezolid is currently indicated to treat vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia caused by Staphylococcus aureus or Streptococcus pneumoniae, complicated and uncomplicated skin and skin structure infections, and community-acquired pneumonia. We report a case...

  • Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci. Kainer, Marion A.; Devasia, Rose A.; Jones, Timothy F.; Simmons, Bryan P.; Melton, Kelley; Chow, Susan; Broyles, Joyce; Moore, Kelly L.; Craig, Allen S.; Schaffner, William // Emerging Infectious Diseases;Jul2007, Vol. 13 Issue 7, p1024 

    Linezolid was approved in 2000 for treatment of gram-positive coccal infections. We performed a case-control study during a hospital outbreak of linezolid-resistant enterococci (LRE) infections, comparing cases of LRE infection (cases) with linezolid-sensitive enterococci infections (controls)....

  • Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation. Hayakawa, K.; Marchaim, D.; Bathina, P.; Martin, E.; Pogue, J.; Sunkara, B.; Kamatam, S.; Ho, K.; Willis, L.; Ajamoughli, M.; Patel, D.; Khan, A.; Lee, K.; Suhrawardy, U.; Jagadeesh, K.; Reddy, S.; Levine, M.; Ahmed, F.; Omotola, A.; Mustapha, M. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2013, Vol. 32 Issue 6, p815 

    In the majority of cases of vancomycin-resistant Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus faecalis (VR E. faecalis) served as the vanA donor to S. aureus. Previous studies that evaluated the risk factors for co-colonization with VRE and MRSA did not differentiate between...

  • New Perspectives on Fluoroquinolones.  // Review of Optometry;6/15/2007 Supplement, Vol. 144, p14A 

    The article offers perspective on fluoroquinolones. It focuses on the article titled "In Vitro of Fluoroquinolones, Vanocomycin and Gentamicin Against Methicilin-Resistant Staphylococcus aureus (MRSA) Ocular Isolates" which concludes that MRSA ocular isolates exhibited a relatively high rate of...

  • Community-Associated MRSA Infections Are on the Rise.  // Pulmonary Reviews;Nov2007, Vol. 12 Issue 11, p14 

    The article addresses the increasing number of community-associated methicillin-resistant Staphylococcus aureus (MRSA) infections in the U.S. A study by R. Monina Klevens and colleagues, published in the October 17, 2007 issue of the "Journal of the American Medical Association," revealed that...

  • Synergistic antimicrobial activity between pentacyclic triterpenoids and antibiotics against Staphylococcus aureus strains. Pooi Yin Chung; Navaratnam, Parasakthi; Lip Yong Chung // Annals of Clinical Microbiology & Antimicrobials;2011, Vol. 10 Issue 1, p25 

    Background: There has been considerable effort to discover plant-derived antibacterials against methicillinresistant strains of Staphylococcus aureus (MRSA) which have developed resistance to most existing antibiotics, including the last line of defence, vancomycin. Pentacyclic triterpenoid, a...

  • Antibiotic Treatment of Diabetic Foot Infections. Deresinski, Stan // Clinical Infectious Diseases;2/1/2006, Vol. 42 Issue 3, preceding p315 

    The article focuses on a research conducted on patients with diabetic foot infections regarding antibiotic treatments. Patients were given either ertapenem (1 g daily) or piperacillin-tazobactam (PT) (3.375 g every 6 hour). Among patients from whom methicillin-resistant Staphylococcus aureus was...

  • Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections. Deresinski, Stan // Clinical Infectious Diseases;10/1/2009, Vol. 49 Issue 7, p1072 

    Vancomycin is often combined with a second antibiotic, most often rifampin or gentamicin, for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Published data from experiments evaluating these and other vancomycin-based combinations, both in vitro and in animal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics